Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human granulocyte colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is a synthetic version of the endogenous cytokine G-CSF, produced using recombinant DNA technology (typically in *E. coli* or mammalian cell systems). It acts as an agonist of the granulocyte colony-stimulating factor receptor (CSF3R), stimulating the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils in the bone marrow. It also promotes the release of mature neutrophils and hematopoietic stem cells from the bone marrow into the peripheral blood. Clinically, rhG-CSF (such as filgrastim or lenograstim) is widely used to prevent and treat chemotherapy-induced neutropenia, reduce the risk of infection in patients with non-myeloid malignancies, and mobilize autologous or allogeneic peripheral blood progenitor cells for hematopoietic stem cell transplantation.
- Brand names
- GranGranocyteNeu-upNeupogen
- Other names
- G-CSFgranulocyte colony-stimulating factorrecombinant human G-CSFrecombinant human granulocyte colony-stimulating factorrhG-CSF
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on recombinant human granulocyte colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human granulocyte colony-stimulating factor.